We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

BIO-RAD LABORATORIES

Provides full range of instrumentation, reagent kits, software and quality control systems to clinical laboratories. ... read more Featured Products: More products

Download Mobile App





Bio-Rad Launches SARS-CoV-2 S Gene Alpha, Beta, Gamma, and Epsilon Variant Controls

By LabMedica International staff writers
Posted on 17 Aug 2021
Print article
Image: Bio-Rad Launches SARS-CoV-2 S Gene Alpha, Beta, Gamma, and Epsilon Variant Controls (Photo courtesy of Bio-Rad Laboratories)
Image: Bio-Rad Launches SARS-CoV-2 S Gene Alpha, Beta, Gamma, and Epsilon Variant Controls (Photo courtesy of Bio-Rad Laboratories)
Bio-Rad Laboratories (Hercules, CA, USA) has launched SARS-CoV-2 S Gene Variant Controls which are intended to be validated as independent external run controls and used for research testing with molecular assays targeting mutations in the Spike (S) gene of SARS-CoV-2 variants to monitor assay performance.

These Exact Diagnostics SARS-CoV-2 S Gene Variant Controls are to be used with assays detecting SARS-CoV-2 variant RNA and to be processed in the same manner as patient specimens to monitor all the steps of molecular assays. The Exact Diagnostics SARS-CoV-2 S Gene Alpha Variant Control consists of a synthetic RNA transcript of the Alpha variant SARS-CoV-2 S gene (Lineage B.1.1.7) in a matrix simulating transport media. This product also contains human genomic DNA (human gDNA; which includes the human RNase P) for internal control needs, allowing laboratories to monitor the entire process of a molecular assay including extraction, amplification, and detection. The extraction of this product is optional.

The Exact Diagnostics SARS-CoV-2 S Gene Beta Variant Control consists of a synthetic RNA transcript of the Beta variant SARS-CoV-2 S gene (Lineage B.1.351) in a matrix simulating transport media. This product also contains human genomic DNA (human gDNA; which includes the human RNase P) for internal control needs, allowing laboratories to monitor the entire process of a molecular assay including extraction, amplification, and detection. The extraction of this product is optional.

The Exact Diagnostics SARS-CoV-2 S Gene Epsilon Variant Control consists of a synthetic RNA transcript of the Epsilon variant SARS-CoV-2 S gene (Lineage B.1.429) in a matrix simulating transport media. This product also contains human genomic DNA (human gDNA; which includes the human RNase P) for internal control needs, allowing laboratories to monitor the entire process of a molecular assay including extraction, amplification, and detection. The extraction of this product is optional.

The Exact Diagnostics SARS-CoV-2 S Gene Gamma Variant Control consists of a synthetic RNA transcript of the Gamma variant SARS-CoV-2 S gene (Lineage P.1) in a matrix simulating transport media. This product also contains human genomic DNA (human gDNA; which includes the human RNase P) for internal control needs, allowing laboratories to monitor the entire process of a molecular assay including extraction, amplification, and detection. The extraction of this product is optional.



New
Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Creatine Kinase-MB Assay
CK-MB Test
New
Silver Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.